Isoniazid pharmacokinetics in children treated for respiratory tuberculosis. 2005

H S Schaaf, and D P Parkin, and H I Seifart, and C J Werely, and P B Hesseling, and P D van Helden, and J S Maritz, and P R Donald
Department of Paediatrics and Child Health, Faculty of Health Sciences, Stellenbosch University, Tygerberg Children's Hospital, South Africa. hss@sun.ac.za

OBJECTIVE To define the pharmacokinetics of isoniazid (INH) in children with tuberculosis in relation to the N-acetyltransferase 2 (NAT2) genotype. METHODS The first order elimination rate constant (k) and area under the concentration curve (AUC) were calculated in 64 children <13 years of age (median 3.8) with respiratory tuberculosis from INH concentrations determined 2-5 hours after a 10 mg/kg INH dose. The NAT2 genotype was determined; 25 children were classified as homozygous slow (SS), 24 as heterozygous fast (FS), and 15 as homozygous fast (FF) acetylators. RESULTS The mean (SD) k values of the genotypes differed significantly from one another: SS 0.254 (0.046), FS 0.513 (0.074), FF 0.653 (0.117). Within each genotype a median regression of k on age showed a significant decrease in k with age. The mean (SD) INH concentrations (mg/l) two hours after INH administration were SS 8.599 (1.974), FS 5.131 (1.864), and FF 3.938 (1.754). A within genotype regression of 2-hour INH concentrations on age showed a significant increase with age. A within genotype regression of 3-hour, 4-hour, and 5-hour concentrations on age also showed a significant increase with age in each instance. In ethnically similar adults, mean (SD) 2-hour INH concentrations (mg/l) for each genotype were significantly higher than the children's: SS 10.942 (1.740), FS 8.702 (1.841), and FF 6.031 (1.431). CONCLUSIONS Younger children eliminate INH faster than older children and, as a group, faster than adults, and require a higher mg/kg body weight INH dose to achieve serum concentrations comparable to adults.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D007538 Isoniazid Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis. Isonicotinic Acid Hydrazide,Ftivazide,Isonex,Isonicotinic Acid Vanillylidenehydrazide,Phthivazid,Phthivazide,Tubazide,Acid Vanillylidenehydrazide, Isonicotinic,Hydrazide, Isonicotinic Acid,Vanillylidenehydrazide, Isonicotinic Acid
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D005838 Genotype The genetic constitution of the individual, comprising the ALLELES present at each GENETIC LOCUS. Genogroup,Genogroups,Genotypes
D006579 Heterozygote An individual having different alleles at one or more loci regarding a specific character. Carriers, Genetic,Genetic Carriers,Carrier, Genetic,Genetic Carrier,Heterozygotes
D006720 Homozygote An individual in which both alleles at a given locus are identical. Homozygotes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

H S Schaaf, and D P Parkin, and H I Seifart, and C J Werely, and P B Hesseling, and P D van Helden, and J S Maritz, and P R Donald
March 2010, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease,
H S Schaaf, and D P Parkin, and H I Seifart, and C J Werely, and P B Hesseling, and P D van Helden, and J S Maritz, and P R Donald
September 1980, European journal of pediatrics,
H S Schaaf, and D P Parkin, and H I Seifart, and C J Werely, and P B Hesseling, and P D van Helden, and J S Maritz, and P R Donald
October 1983, Pediatrics,
H S Schaaf, and D P Parkin, and H I Seifart, and C J Werely, and P B Hesseling, and P D van Helden, and J S Maritz, and P R Donald
March 1977, Acta paediatrica Scandinavica,
H S Schaaf, and D P Parkin, and H I Seifart, and C J Werely, and P B Hesseling, and P D van Helden, and J S Maritz, and P R Donald
June 2014, Journal of the Pediatric Infectious Diseases Society,
H S Schaaf, and D P Parkin, and H I Seifart, and C J Werely, and P B Hesseling, and P D van Helden, and J S Maritz, and P R Donald
January 2019, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease,
H S Schaaf, and D P Parkin, and H I Seifart, and C J Werely, and P B Hesseling, and P D van Helden, and J S Maritz, and P R Donald
January 1962, Lille medical : journal de la Faculte de medecine et de pharmacie de l'Universite de Lille,
H S Schaaf, and D P Parkin, and H I Seifart, and C J Werely, and P B Hesseling, and P D van Helden, and J S Maritz, and P R Donald
January 1985, Pediatric infectious disease,
H S Schaaf, and D P Parkin, and H I Seifart, and C J Werely, and P B Hesseling, and P D van Helden, and J S Maritz, and P R Donald
March 2020, Pediatric pulmonology,
H S Schaaf, and D P Parkin, and H I Seifart, and C J Werely, and P B Hesseling, and P D van Helden, and J S Maritz, and P R Donald
January 1985, Sovetskaia meditsina,
Copied contents to your clipboard!